Condition: Hypoparathyroidism · Sponsor: Ascendis Pharma A/S
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
This description comes directly from the study's public registry record.
Yorvipath Pregnancy Inquiries · 877-229-2184 · yorvipathpregnancy@ubc.com
Always discuss trial participation with your own doctor first.
| Ascendis Investigational Site | Morgantown, West Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07345494